Characteristics of the 61 patients analyzed
Characteristic . | Value* . |
---|---|
Sex, no. M/no. F patients | 32/29 |
Median age at transplantation, y (range) | 9 (1-24) |
Underlying disease | |
Malignant | 37 (61) |
Nonmalignant | 24 (39) |
Stem-cell source | |
Bone marrow | 43 (70) |
Peripheral blood | 14 (23) |
Cord blood | 4 (7) |
Donor type | |
Sibling | 22 (36) |
Unrelated | 27 (44) |
Haploidentical relative | 12 (20) |
Donor/recipient HCMV serostatus | |
D+/R+ | 28 (46) |
D-/R+ | 11 (18) |
D+/R- | 18 (29) |
D-/R- | 4 (7) |
Conditioning regimen | |
TBI based | 27 (44) |
Non-TBI based | 34 (56) |
GvHD prophylaxis | |
CS-A | 13 (21) |
CS-A + MTX | 36 (59) |
T-cell depletion | 12 (20) |
Administration of ALG | |
Yes | 27 (44) |
No | 34 (56) |
GvHD grade | |
0 to I | 44 (72) |
II to IV | 17 (28) |
Steroid therapy | |
Yes | 26 (43) |
No | 35 (57) |
Characteristic . | Value* . |
---|---|
Sex, no. M/no. F patients | 32/29 |
Median age at transplantation, y (range) | 9 (1-24) |
Underlying disease | |
Malignant | 37 (61) |
Nonmalignant | 24 (39) |
Stem-cell source | |
Bone marrow | 43 (70) |
Peripheral blood | 14 (23) |
Cord blood | 4 (7) |
Donor type | |
Sibling | 22 (36) |
Unrelated | 27 (44) |
Haploidentical relative | 12 (20) |
Donor/recipient HCMV serostatus | |
D+/R+ | 28 (46) |
D-/R+ | 11 (18) |
D+/R- | 18 (29) |
D-/R- | 4 (7) |
Conditioning regimen | |
TBI based | 27 (44) |
Non-TBI based | 34 (56) |
GvHD prophylaxis | |
CS-A | 13 (21) |
CS-A + MTX | 36 (59) |
T-cell depletion | 12 (20) |
Administration of ALG | |
Yes | 27 (44) |
No | 34 (56) |
GvHD grade | |
0 to I | 44 (72) |
II to IV | 17 (28) |
Steroid therapy | |
Yes | 26 (43) |
No | 35 (57) |
TBI indicates total body irradiation; CS-A, cyclosporine-A; MTX, methotrexate; ALG, antilymphocyte globulin; and GvHD, graft-versus-host disease.
Values are expressed as number of patients (percent of patients) unless otherwise indicated.